

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	CREKA and homing	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/02/06 16:50
L2	1	CREKA and hom\$	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/02/06 16:50
L3	2	\$CREKA\$	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/02/06 16:50
S1	1	10/233153	US-PGPUB; USPAT	OR	OFF	2007/02/05 16:59
S2	0	60/509048	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/02/06 16:50

**SCORE Search Results Details for Application
10648813 and Search Result
20050310_162609_us-10-648-813-1.oligo.rag.**

Score Home	Retrieve Application	SCORE System	SCORE	Comments /
Page	List	Overview	FAQ	Suggestions

This page gives you Search Results detail for the Application 10648813 and Search Result 20050310_162609_us-10-648-813-1.oligo.rag.

[start](#) | [next page](#)

[Go Back to previous page](#)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

```
Run on:      March 14, 2005, 10:17:17 ; Search time 75 Seconds
              (without alignments)
              25.784 Million cell updates/sec
```

Title: US-10-648-813-1
Perfect score: 5
Sequence: 1 CREKA 5

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 2105692 seqs, 386760381 residues

Word size : 0

Total number of hits satisfying chosen parameters: 2105692

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing: Listing first 45 summaries

```
Database :      A_Geneseq_16Dec04:*
1:  geneseqp1980s:*
2:  geneseqp1990s:*
3:  geneseqp2000s:*
4:  geneseqp2001s:*
5:  geneseqp2002s:*
6:  geneseqp2003as:*
7:  geneseqp2003bs:*
8:  geneseqp2004s:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	$\frac{2}{3}$ Query
--------	------------------------

No.	Score	Match	Length	DB	ID	Description
1	5	100.0	52	5	ABP04218	Abp04218 Human ORF
2	5	100.0	53	4	AAM90878	Aam90878 Human imm
3	5	100.0	73	8	ABO55771	Abo55771 Human gen
4	5	100.0	85	4	AAM91923	Aam91923 Human dig
5	5	100.0	124	4	AAO01862	Aao01862 Human pol
6	5	100.0	165	4	ABG02425	Abg02425 Novel hum
7	5	100.0	165	5	ABP64374	Abp64374 Human ORF
8	5	100.0	192	6	ABU45289	Abu45289 Protein e
9	5	100.0	228	4	ABG03613	Abg03613 Novel hum
10	5	100.0	256	8	ADN25976	Adn25976 Bacterial
11	5	100.0	299	6	AAE36172	Aae36172 Human CGD
12	5	100.0	308	3	AAG07076	Aag07076 Arabidops
13	5	100.0	308	3	AAG53865	Aag53865 Arabidops
14	5	100.0	361	3	AAG53864	Aag53864 Arabidops
15	5	100.0	361	3	AAG07075	Aag07075 Arabidops
16	5	100.0	374	4	ABB61137	Abb61137 Drosophil
17	5	100.0	432	4	ABB59629	Abb59629 Drosophil
18	5	100.0	437	4	AAB95338	Aab95338 Human pro
19	5	100.0	437	6	ABO07253	Abo07253 Human p53
20	5	100.0	437	7	ADJ69372	Adj69372 Human hea
21	5	100.0	474	2	AAW22518	Aaw22518 Heat-resi
22	5	100.0	530	4	ABB66370	Abb66370 Drosophil
23	5	100.0	530	4	ABB71272	Abb71272 Drosophil
24	5	100.0	548	4	AAB30571	Aab30571 A full le
25	5	100.0	548	4	AAB30572	Aab30572 A full le
26	5	100.0	591	4	ABG04012	Abg04012 Novel hum
27	5	100.0	591	4	ABG16987	Abg16987 Novel hum
28	5	100.0	591	4	ABG03404	Abg03404 Novel hum
29	5	100.0	764	7	ABO72987	Abo72987 Pseudomon
30	5	100.0	815	4	ABG12470	Abg12470 Novel hum
31	5	100.0	1202	7	ADE60833	Ade60833 Rat Prote
32	5	100.0	1494	7	ADD25143	Add25143 Fertility
33	5	100.0	1494	8	ADN61158	Adn61158 Radish nu
34	5	100.0	2272	4	ABB70004	Abb70004 Drosophil
35	4	80.0	9	2	AAW60480	Aaw60480 Tumour ho
36	4	80.0	9	2	AAW93807	Aaw93807 Human Kap
37	4	80.0	9	3	AAB21897	Aab21897 Human Kap
38	4	80.0	9	4	AAE06475	Aae06475 Tumour ho
39	4	80.0	10	4	AAG83615	Aag83615 Arabidops
40	4	80.0	10	4	AAG83609	Aag83609 Arabidops
41	4	80.0	10	4	AAG83607	Aag83607 Arabidops
42	4	80.0	10	4	AAG83613	Aag83613 Arabidops
43	4	80.0	10	4	AAG95103	Aag95103 Human com
44	4	80.0	10	6	ABB99630	Abb99630 Amino aci
45	4	80.0	11	5	AAE18607	Aae18607 Rat gamma

ALIGNMENTS

RESULT 1

ABP04218

ID ABP04218 standard; protein; 52 AA.

XX

AC ABP04218;

XX

DT 24-JUN-2002 (first entry)

XX

DE Human ORFX protein sequence SEQ ID NO:8418.

XX

KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;

KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
 KW hypertension; hypothyroidism; cholesterol ester storage disease;
 KW immune deficiency; immune disorder; infectious disease;
 KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
 KW myasthenia gravis.
 XX
 OS Homo sapiens.
 XX
 PN WO200192523-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 29-MAY-2001; 2001WO-US010836.
 XX
 PR 30-MAY-2000; 2000US-0206132P.
 PR 29-AUG-2000; 2000US-0228716P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Shimkets RA, Leach MD;
 XX
 DR WPI; 2002-106308/14.
 DR N-PSDB; ABN19970.
 XX
 PT Novel human polypeptides and polynucleotides useful for diagnosing,
 PT preventing and treating cardiovascular disease, neurodegenerative,
 PT hyperproliferative disorders and autoimmune disorders.
 XX
 PS Disclosure; SEQ ID NO 8418; 1037pp; English.
 XX
 CC The present invention describes substantially purified human proteins
 CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
 CC in the specification). ABN15762 to ABN27252 encode the human ORFX
 CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
 CC treating or preventing a pathology associated with an ORFX-associated
 CC disorder in humans, and in the manufacture of a medicament for treating a
 CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
 CC sequences can be used in gene therapy. ORFX sequences can be used in the
 CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
 CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
 CC osteoarthritis, neurodegenerative disorders, disorders related to organ
 CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
 CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
 CC storage disease, various immune deficiencies and disorders, infectious
 CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
 CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
 CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
 CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
 CC bone degenerative disorders, or periodontal disease, and for gut
 CC protection or regeneration and treatment of lung or liver fibrosis,
 CC reperfusion injury in various tissues and conditions resulting from
 CC systemic cytokine damage. N.B. The sequence data for this patent did not
 CC form part of the printed specification, but was obtained in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 52 AA;

Query Match 100.0%; Score 5; DB 5; Length 52;
 Best Local Similarity 100.0%; Pred. No. 64;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1 CREKA 5
Db	26 CREKA 30